
Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Free Report) – Research analysts at HC Wainwright upped their FY2026 EPS estimates for shares of Milestone Pharmaceuticals in a report released on Monday, November 16th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($0.85) for the year, up from their prior forecast of ($0.86). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ Q4 2026 earnings at ($0.26) EPS, FY2027 earnings at ($0.64) EPS, FY2028 earnings at ($0.29) EPS, FY2029 earnings at ($0.11) EPS and FY2030 earnings at $0.47 EPS.
Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. Milestone Pharmaceuticals had a negative net margin of 1,860.76% and a negative return on equity of 435.88%. The firm had revenue of $2.96 million during the quarter, compared to analysts’ expectations of $1.00 million.
Read Our Latest Report on Milestone Pharmaceuticals
Milestone Pharmaceuticals Stock Performance
Shares of MIST stock opened at $0.40 on Wednesday. The stock’s 50-day moving average is $0.75 and its two-hundred day moving average is $1.28. The company has a quick ratio of 7.92, a current ratio of 6.27 and a debt-to-equity ratio of 3.25. Milestone Pharmaceuticals has a 1 year low of $0.36 and a 1 year high of $3.06.
Institutional Trading of Milestone Pharmaceuticals
A number of large investors have recently bought and sold shares of the business. HighTower Advisors LLC raised its holdings in shares of Milestone Pharmaceuticals by 100.0% in the second quarter. HighTower Advisors LLC now owns 20,000 shares of the company’s stock valued at $27,000 after buying an additional 10,000 shares during the last quarter. Bay Rivers Group boosted its stake in shares of Milestone Pharmaceuticals by 55.9% during the second quarter. Bay Rivers Group now owns 46,633 shares of the company’s stock worth $62,000 after buying an additional 16,722 shares during the period. Waterloo Capital L.P. acquired a new stake in shares of Milestone Pharmaceuticals during the third quarter worth about $40,000. Pinnacle Wealth Planning Services Inc. acquired a new stake in shares of Milestone Pharmaceuticals during the third quarter worth about $68,000. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Milestone Pharmaceuticals during the second quarter worth about $134,000. Institutional investors and hedge funds own 86.18% of the company’s stock.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cardiovascular conditions. Its work centers on therapies intended to give patients and caregivers options for managing acute heart rhythm episodes outside of a clinical setting. The company’s lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. It is designed for self-administration to treat episodes of paroxysmal supraventricular tachycardia, a condition involving sudden episodes of abnormally fast heart rate.
Recommended Stories
- Five stocks we like better than Milestone Pharmaceuticals
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
